Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 4: 694 - 702

DOI: https://doi.org/10.19852/j.cnki.jtcm.20240627.001

Original articles

Zhuangyao Jianshen pill (壮腰健肾丸) ameliorates testosterone-induced benign postatic hyperplasia in rats

  • Jingrui ZHENG ,
  • Weijian CHEN ,
  • Binbin YE ,
  • Ziyao MO ,
  • Qunqun DU ,
  • Renan QIN ,
  • Ke NIE
Expand
  • 1 School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
    2 Modern Chinese Medicine Research Institute, Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd., Guangzhou 510228, China

Received date: 2023-03-21

  Accepted date: 2023-09-05

  Online published: 2024-06-27

Fold

Abstract

OBJECTIVE: To determine the therapeutic effects of the Zhuangyao Jianshen pill (壮腰健肾丸, ZYJSP) against benign prostatic hyperplasia (BPH) and investigate the underlying mechanism.

METHODS: Forty-eight male Sprague-Dawley rats were randomly divided into six groups: Control group, BPH model group, finasteride-treated group, ZYJSP low, medium and high dose groups. Except for the control group, 40 rats were castrated and injected with testosterone propionate (TP) for 28 consecutive day to induce BPH. Meanwhile, the corresponding drugs were administered by gavage. The prostate wet weight, prostate index (PI), and the histopathological changes in the prostate were measured as the basis for examining the efficacy of ZYJSP against BPH. Levels of the serum sex hormones, oxidative stress markers, inflammatory markers, renal function markers, growth factors, and Cyclin D1 expression in prostate were measured to characterize the therapeutic mechanism of ZYJSP against BPH.

RESULTS: ZYJSP administration significantly reduced prostate wet weight and PI and ameliorated histological changes of the prostate in TP-treated castrated rats. TP markedly increased the levels of creatinine, blood urea nitrogen and growth factors in the serum as well as the expression of the Cyclin D1 in the prostate. Most of these markers were significantly decreased by ZYJSP. ZYJSP significantly restored the dysregulation of testosterone, estradiol, and dihydrotestosterone caused by TP. Furthermore, ZYJSP relieved TP-induced prostate injury and exhibited both anti-inflammatory and anti-oxidant activity by decreasing interleukin-6, interleukin-8, and malondialdehyde levels and increasing the activity of superoxide dismutase in the serum.

CONCLUSION: These findings indicate that ZYJSP can effectively ameliorate BPH induced by TP in castrated rats, and the underlying mechanism might be related to regulating sex hormone balance, reducing oxidative stress, and inhibiting the inflammatory response.

Key words： prostatic hyperplasia; rat; testosterone propionate; Zhuangyao Jianshen pill

Cite this article

Jingrui ZHENG , Weijian CHEN , Binbin YE , Ziyao MO , Qunqun DU , Renan QIN , Ke NIE . Zhuangyao Jianshen pill (壮腰健肾丸) ameliorates testosterone-induced benign postatic hyperplasia in rats[J]. Journal of Traditional Chinese Medicine, 2024 , 44(4) : 694 -702 . DOI: 10.19852/j.cnki.jtcm.20240627.001

References

1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248-57.
2. Stroup SP, Palazzi-Churas K, Kopp RP, et al. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012; 109: 84-7.
3. Minh TD, Thanh Ha TN, Duy TN, et al. Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate. J Ethnopharmacol 2021; 279: 114388.
4. Zuo T, Guo L, Miao M. Effects of Wuji Baifeng Wan on biochemical indexes and tissue morphology in benign prostate hyperplasia rats. Zhong Hua Zhong Yi Yao Za Zhi 2015; 30: 3253-6.
5. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61: 2-7.
6. Jin BR, Kim HJ, Park SK, et al. Anti-proliferative effects of hbx-5 on progression of benign prostatic hyperplasia. Molecules 2018; 23: 2638.
7. Xue B, Wu S, Sharkey C, et al. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostatic Dis 2020; 23: 465-74.
8. Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66: 5012-20.
9. Nicholson TM, Moses MA, Uchtmann KS, et al. Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J Urol 2015; 193: 722-9.
10. Cao DH, Liu LR, Li L, et al. Pathological characteristics of CD40/CD40L and NF-κB proteins related to inflammation in benign prostatic hyperplasia tissue: a retrospective study of 120 cases. Int J Clin Exp Pathol 2017; 10: 10863-72.
11. Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase Ⅱ drug metabolism enzymes and Phase Ⅲ drug transporters. Biopharm Drug Dispos 2009; 30: 345-55.
12. Zhang L, Xie H, Yan M, et al. Effects of Kelong capsule on benign prostatic hyperplasia rat model and Nrf2/ARE signaling pathway. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2018; 24: 87-91.
13. Yang X, Yuan L, Xiong C, et al. Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 2014; 157: 105-13.
14. Duclos AJ, Lee CT, Shoskes DA. Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag 2007; 3: 507-12.
15. Traish AM. Health risks associated with long-term finasteride and dutasteride use: it's time to sound the alarm. World J Mens Health 2020; 38: 323-37.
16. Lyu Y. Pharmacological study on Zhuangyao Jianshen pill. Zhong Yao Cai 1993; 9: 36-8.
17. Lian Q, He F, Mo G, et al. Effect of Zhuangyao Jianshen Wan on the reproductive system in mice. Guangdong Yao Ke Da Xue Xue Bao 2015; 31: 215-8.
18. Li G, Xu Z, Lu Y, Li C. Gene chip study on the anti-oxidative and anti-aging effects of Zhuangyao Jianshen pill. Zhong Yao Cai 2006; 37: 365-7.
19. Hu J, Hu Z. Effects of Zhuangyao Jianshen pill on blood routine and serum biochemical indexes of immunosuppressed mice. You Jiang Min Zu Yi Xue Yuan Xue Bao 2021; 43: 460-4.
20. Kim SR, Ha AW, Choi HJ, et al. Corn silk extract improves benign prostatic hyperplasia in experimental rat model. Nutr Res Pract 2017; 11: 373-80.
21. Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013; 112: 432-41.
22. Cai H, Zhang G, Yan Z, et al. The effect of Xialiqi capsule on testosterone-induced benign prostatic hyperplasia in rats. Evid Based Complement Alternat Med 2018; 2018: 5367814.
23. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-57.
24. Wang Z, Hu L, Salari K, et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. J Pathol 2017; 243: 457-67.
25. Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators Inflamm 2020; 2020: 7958316.
26. Yang L, Huang C, Lang D, et al. Effects of Lycium barbarum flavonoids on serum sex hormones in benign prostatic hyperplasia rats. Heilongjiang Xu Mu Shou Yi 2015; 19: 240-1+4.
27. Ghosh D, Egbuta C, Lo J. Testosterone complex and non-steroidal ligands of human aromatase. J Steroid Biochem Mol Biol 2018; 181: 11-9.
28. Wu Q, Zhou Y, Chen L, et al. Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2. J Endocrinol 2007; 195: 89-94.
29. Jin BR, Ju JY, Nugroho A, et al. Carica papaya leaf extract inhibits prostatitis-associated prostatic hyperplasia via the TRAF6/TAK1/MEK/NF-κB pathway. Biomed Pharmacother 2021; 135: 111197.
30. Lotti F, Maggi M. Interleukin 8 and the male genital tract. J Reprod Immunol 2013; 100: 54-65.
31. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83: 1131-46.
32. Kullisaar T, Türk S, Punab M, et al. Oxidative stress--cause or con-sequence of male genital tract disorders? Prostate 2012; 72: 977-83.
33. Hamid AR, Umbas R, Mochtar CA. Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Medica Indonesiana. 2011; 43: 59-65.
34. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000; 28: 1745-50.
35. Guo X. Study on the mechanism and clinical of rape bee pollen against benign prostatic hyperplasia. Shanghai: Shanghai Jiao Tong University, 2019: 25-6+9.
36. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619-22.
37. Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010; 2010: CD006015.
38. Oosterhoff JK, Grootegoed JA, Blok LJ. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling. Endocr Relat Cancer 2005; 12: 135-48.
39. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur urol 2011; 60: 106-17.
40. Abdel-Naim AB, Neamatallah T, Eid BG, et al. Ashour OM. α2-methoxyestradiol attenuates testosterone-induced benign prostate hyperplasia in rats through inhibition of HIF-1α/TGF-β/Smad2 axis. Oxid Med Cell Longev 2018; 2018: 4389484.
41. Abo-Youssef AM, Afify H, Azouz AA, Abdel-Rahman HM, Abdel-Naim AB, Allam S. Febuxostat attenuates testosterone-induced benign prostatic hyperplasia in rats via inhibiting JAK/STAT axis. Life Sci 2020; 260: 118414.
42. Valdivielso JM, Jacobs-Cachá C, Soler MJ. Sex hormones and their influence on chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28: 1-9.
43. Park KM, Kim JI, Ahn Y, et al. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem 2004; 279: 52282-92.
44. Chen Y, Jin S, Teng X, et al. Hydrogen sulfide attenuates LPS-induced acute kidney injury by inhibiting inflammation and oxidative stress. Oxid Med Cell Longev 2018; 2018: 6717212.
45. Feng W. The value assessment of the relevant indicators concerning impaired renal function caused by benign prostatic hyperplasia. Chongqing: Chongqing Medical University, 2012: 8.
Options
Outlines

/

〈 〉